BASF refuses to increase the valuation again
BASF ended its effort to acquire Evonik on 19 November after the target rejected two non-binding all-cash proposals. BASF’s final disclosed offer valued Evonik at €24 per share, or about €11.2 billion. Although BASF had indicated that it might consider a further moderate increase, it said Evonik had not engaged meaningfully and that its assessment of the target’s standalone prospects and risks did not justify a higher price. The announcement converts months of takeover uncertainty into two separate strategic paths.[1][2]
Evonik preferred independence over promised scale
Evonik’s interim chief executive said the company could now concentrate on independent development and remove uncertainty for employees. People close to Evonik had told Reuters that price alone would not produce support because the target did not see a compelling industrial rationale. BASF had argued that a combination could create a stronger European chemicals company and protect jobs against more disruptive foreign approaches. Those competing claims were never tested through a signed agreement or public synergy plan.[1][2]
The market repriced the probability of a takeover
Evonik shares fell about 16% to roughly €18 after the withdrawal, while BASF declined modestly. The asymmetric reaction indicates that Evonik’s price had incorporated a substantial probability of receiving BASF’s cash consideration. It does not prove that independence destroys value; it reflects the removal of an immediate premium. BASF, meanwhile, emphasized capital discipline and shareholder distributions, signaling that acquisitions remain optional within its Winning Ways strategy rather than necessary for meeting its portfolio objectives.[1][2]
Structural pressure on European chemistry remains
The failed transaction does not remove the forces that prompted it. European chemical producers face elevated energy and feedstock costs, uneven end demand and strong Asian competition. Germany’s October producer-price data showed basic chemicals up 12.5% and distributed natural gas up 21.9% year on year. Consolidation might offer purchasing, production and administrative efficiencies, but it can also create integration costs, antitrust problems and politically sensitive plant decisions. Both companies must now demonstrate that their standalone investment plans can address those pressures without the proposed scale benefits.[1][2][3]
Sources & evidence
- BASF ends efforts to acquire Evonik and reaffirms disciplined approach to capital allocation (opens in a new tab)BASFSource language en
Withdrawal, two rejected offers, €24 price, valuation reasoning and capital-allocation position.
Source note
Public company release was read and is not treated as independent confirmation.
- BASF ends pursuit of Evonik after $12 billion bid rejected (opens in a new tab)Reuters via MarketScreenerSource language en
Evonik response, market reaction, offer history and reported disagreement over industrial rationale.
Source note
Public syndicated Reuters text was read.
- Producer prices in October 2026: +8.1% on October 2025 (opens in a new tab)German Federal Statistical Office (Destatis)Source language en
Current German chemical and energy input-price context.
Source note
Public full text was read.